A gene-based anti-angiogenesis therapy as a novel strategy for cancer treatment

In this study, we have developed a gene-based anti-VEGF mAb system which is expected to produce a high concentration of anti-VEGFA mAb upon a single administration in cancer patients. The full-length cDNA bevacizumab light and heavy chains joint with T2A sequence were cloned in pCDH lentivirus vector. The lentiviral particles expressing bevacizumab was produced in HEK-293 T cells. Recombinant lentiviral particles containing bevacizumab (rLV-bev) efficiently transduced HEK-293 cells and produced functional bevacizumab mAb. Bevacizumab expression in the transduced cell was assessed by qRT-PCR and western blot at both the mRNA and protein level, respectively. The functionality of the recombinant bevacizumab was confirmed using the tube formation assay in the co-culture system of endothelial cells and HT-29 cells transduced with rLV-bev viral particles. Our results show that tLV-bev gene delivery system can be useful for angiogenesis-targeted therapy of cancer.
Source: Life Sciences - Category: Biology Source Type: research